# Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

> **NCT03802058** · PHASE2 · TERMINATED · sponsor: **Wuhan University** · enrollment: 24 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung
- Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nab-paclitaxel
- **DRUG:** Carboplatin
- **RADIATION:** Thoracic radiation therapy

## Key facts

- **NCT ID:** NCT03802058
- **Lead sponsor:** Wuhan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-03-20
- **Primary completion:** 2021-12-12
- **Final completion:** 2021-12-12
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** The study was halted because enrollment was too slow
- **Last updated:** 2023-04-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03802058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03802058, "Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03802058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*